肝损伤
药品
芯片上器官
药物代谢
体内
人肝
肝病
药物开发
肝功能
药物毒性
微流控芯片
药理学
生物
生物信息学
医学
计算机科学
微流控
炸薯条
纳米技术
内科学
体外
材料科学
生物技术
电信
生物化学
作者
Ehsanollah Moradi,Sasan Jalili‐Firoozinezhad,Mehran Solati‐Hashjin
标识
DOI:10.1016/j.actbio.2020.08.041
摘要
The liver is the largest internal organ of the body with complex microarchitecture and function that plays critical roles in drug metabolism. Hepatotoxicity and drug-induced liver injury (DILI) caused by various drugs is the main reason for late-stage drug failures. Moreover, liver diseases are among the leading causes of death in the world, with the number of new cases arising each year. Although animal models have been used to understand human drug metabolism and toxicity before clinical trials, tridimensional microphysiological systems, such as liver-on-a-chip (Liver Chip) platforms, could better recapitulate features of human liver physiology and pathophysiology and thus, are often more predictive of human outcome. Liver Chip devices have shown promising results in mimicking in vivo condition by recapitulating the sinusoidal structure of the liver, maintaining high cell viability and cellular phenotypes, and emulating native liver functions. Here, we first review the cellular constituents and physiology of the liver and then critically discuss the state-of-the-art chip-based liver models and their applications in drug screening, disease modeling, and regenerative medicine. We finally address the pending issues of existing platforms and touch upon future directions for developing new, advanced on-chip models.
科研通智能强力驱动
Strongly Powered by AbleSci AI